| IV vitamin D use, by DOPPS country and cross-section |
| N Ptnts | Total N | Wgtd % | ||
|---|---|---|---|---|
| DOPPS Country | DOPPS Cross-section | 17 | 508 | 2.6% |
| AusNZ | D2(2002) | |||
| D3(2006) | 8 | 517 | 1.6% | |
| D3(2007) | 16 | 477 | 3.1% | |
| Belgium | D2(2002) | 4 | 536 | 0.8% |
| D3(2006) | 50 | 499 | 12.1% | |
| D3(2007) | 36 | 411 | 8.9% | |
| Canada | D2(2002) | 38 | 591 | 7.1% |
| D3(2006) | 41 | 545 | 5.7% | |
| D3(2007) | 33 | 443 | 5.3% | |
| D4(2010) | 19 | 304 | 3.2% | |
| France | D2(2002) | 39 | 516 | 8.1% |
| D3(2006) | 29 | 548 | 5.2% | |
| D3(2007) | 27 | 542 | 5.0% | |
| D4(2010) | 3 | 349 | 0.7% | |
| Germany | D2(2002) | 57 | 565 | 9.0% |
| D3(2006) | 36 | 576 | 4.9% | |
| D3(2007) | 47 | 620 | 6.3% | |
| D4(2010) | 41 | 541 | 6.8% | |
| Italy | D2(2002) | 74 | 570 | 12.5% |
| D3(2006) | 88 | 520 | 15.4% | |
| D3(2007) | 81 | 540 | 14.4% | |
| D4(2010) | 150 | 425 | 34.0% | |
| Japan | D2(2002) | 210 | 1,763 | 12.5% |
| D3(2006) | 346 | 1,821 | 19.4% | |
| D3(2007) | 376 | 1,846 | 19.6% | |
| D4(2010) | 549 | 1,697 | 31.4% | |
| Spain | D2(2002) | 106 | 597 | 17.4% |
| D3(2006) | 192 | 659 | 29.3% | |
| D3(2007) | 207 | 550 | 37.3% | |
| D4(2010) | 239 | 538 | 44.3% | |
| Sweden | D2(2002) | 118 | 541 | 23.4% |
| D3(2006) | 107 | 535 | 19.9% | |
| D3(2007) | 106 | 507 | 20.2% | |
| D4(2010) | 57 | 434 | 12.7% | |
| UK | D2(2002) | 36 | 549 | 6.9% |
| D3(2006) | 27 | 438 | 5.7% | |
| D3(2007) | 17 | 347 | 4.4% | |
| D4(2010) | 6 | 369 | 1.4% | |
| US | D2(2002) | 1,218 | 2,233 | 55.0% |
| D3(2006) | 1,207 | 1,804 | 66.4% | |
| D3(2007) | 915 | 1,316 | 72.5% | |
| D4(2010) | 2,401 | 3,275 | 74.6% | |
| Medications reported as prescribed (not necessarily taken) in previous week, among all patients |
Please see additional methodological information in the Data Sources and Methods section.